These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 31919692)
21. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092 [TBL] [Abstract][Full Text] [Related]
22. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Sellers TA; Mink PJ; Cerhan JR; Zheng W; Anderson KE; Kushi LH; Folsom AR Ann Intern Med; 1997 Dec; 127(11):973-80. PubMed ID: 9412302 [TBL] [Abstract][Full Text] [Related]
23. Hormone replacement therapy and lung cancer risk in Chinese. Chen KY; Hsiao CF; Chang GC; Tsai YH; Su WC; Perng RP; Huang MS; Hsiung CA; Chen CJ; Yang PC; Cancer; 2007 Oct; 110(8):1768-75. PubMed ID: 17879370 [TBL] [Abstract][Full Text] [Related]
24. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Feigelson HS; Jonas CR; Teras LR; Thun MJ; Calle EE Cancer Epidemiol Biomarkers Prev; 2004 Feb; 13(2):220-4. PubMed ID: 14973094 [TBL] [Abstract][Full Text] [Related]
25. Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and older. Thorbjarnardottir T; Olafsdottir EJ; Valdimarsdottir UA; Olafsson O; Tryggvadottir L Acta Oncol; 2014 Jun; 53(6):752-8. PubMed ID: 24460068 [TBL] [Abstract][Full Text] [Related]
26. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989 [TBL] [Abstract][Full Text] [Related]
27. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414 [TBL] [Abstract][Full Text] [Related]
28. Hormone replacement therapy and the risk of incident congestive heart failure: the Cardiovascular Health Study. Rea TD; Psaty BM; Heckbert SR; Cushman M; Meilahn E; Olson JL; Lemaitre RN; Smith NL; Sotoodehnia N; Chaves PH J Womens Health (Larchmt); 2003 May; 12(4):341-50. PubMed ID: 12804341 [TBL] [Abstract][Full Text] [Related]
29. Early menopause and hormone therapy as determinants for lung health outcomes: a secondary analysis using the PLCO trial. Gai X; Feng Y; Flores TM; Kang H; Yu H; Leslie KK; Zhu Y; Doherty JA; Guo Y; Belinsky SA; Cook LS; Leng S Thorax; 2024 Sep; 79(10):961-969. PubMed ID: 38871464 [TBL] [Abstract][Full Text] [Related]
30. The Risk of Breast Cancer in Women Using Menopausal Hormone Replacement Therapy in Taiwan. Liu JY; Chen TJ; Hwang SJ Int J Environ Res Public Health; 2016 May; 13(5):. PubMed ID: 27187426 [TBL] [Abstract][Full Text] [Related]
31. Hormone replacement therapy in relation to risk of cataract extraction: a prospective study of women. Lindblad BE; Håkansson N; Philipson B; Wolk A Ophthalmology; 2010 Mar; 117(3):424-30. PubMed ID: 20045566 [TBL] [Abstract][Full Text] [Related]
32. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. Kotsopoulos J; Gronwald J; Karlan BY; Huzarski T; Tung N; Moller P; Armel S; Lynch HT; Senter L; Eisen A; Singer CF; Foulkes WD; Jacobson MR; Sun P; Lubinski J; Narod SA; JAMA Oncol; 2018 Aug; 4(8):1059-1065. PubMed ID: 29710224 [TBL] [Abstract][Full Text] [Related]
33. Prediagnostic BMI and thyroid cancer incidence in the PLCO trial. Abdel-Rahman O Future Oncol; 2019 Oct; 15(30):3451-3456. PubMed ID: 31646903 [No Abstract] [Full Text] [Related]
34. Sociodemographic and clinical factors associated with HRT use in women attending menopause clinics in Italy. Pansini F; Bacchi Modena AB; de Aloysio D; Gambacciani M; Meschia M; Parazzini F; Sciacchitano G; di Micco R; Peruzzi E; Maiocchi G; Climacteric; 2000 Dec; 3(4):241-7. PubMed ID: 11910583 [TBL] [Abstract][Full Text] [Related]
35. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. O'Meara ES; Rossing MA; Daling JR; Elmore JG; Barlow WE; Weiss NS J Natl Cancer Inst; 2001 May; 93(10):754-62. PubMed ID: 11353785 [TBL] [Abstract][Full Text] [Related]
36. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. Gapstur SM; Morrow M; Sellers TA JAMA; 1999 Jun; 281(22):2091-7. PubMed ID: 10367819 [TBL] [Abstract][Full Text] [Related]
37. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease. Windler E; Zyriax BC; Eidenmüller B; Boeing H Maturitas; 2007 Jul; 57(3):239-46. PubMed ID: 17292571 [TBL] [Abstract][Full Text] [Related]
38. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Mascarenhas C; Lambe M; Bellocco R; Bergfeldt K; Riman T; Persson I; Weiderpass E Int J Cancer; 2006 Dec; 119(12):2907-15. PubMed ID: 16998830 [TBL] [Abstract][Full Text] [Related]
39. Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. Krabbe LM; Svatek RS; Shariat SF; Messing E; Lotan Y Urol Oncol; 2015 Feb; 33(2):65.e19-25. PubMed ID: 25044253 [TBL] [Abstract][Full Text] [Related]
40. Association of Cigarette, Cigar, and Pipe Use With Mortality Risk in the US Population. Christensen CH; Rostron B; Cosgrove C; Altekruse SF; Hartman AM; Gibson JT; Apelberg B; Inoue-Choi M; Freedman ND JAMA Intern Med; 2018 Apr; 178(4):469-476. PubMed ID: 29459935 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]